CLAIMS

1. Use of an anti-Calcitonin Gene Related Peptide (CGRP) antibody or antibody fragment comprising a light chain variable region (VL) polypeptide comprising complementarity-determining region (CDR) polypeptides comprising the sequences of SEQ ID NO: 55, 56 and 57 and a heavy chain variable region (VH) polypeptide comprising CDR polypeptides comprising the sequences of SEQ ID NO: 58, 59 and 60 in the manufacture of a medicament for treating prediabetes or diabetes in a subject in need thereof.

2. The use of claim 1, wherein the use is for effecting at least one of the following:
(i) increasing peripheral and/or hepatic glucose utilization in the subject;
(ii) decreasing insulin resistance in the subject;
(iii) achieving sustained normoglycemia in the subject;
(iv) delaying the onset of type II diabetes and/or prevent the loss of functional pancreatic beta cells; or
(v) effecting a combination of any of the foregoing.

3. The use of any one of Claims 1-2, wherein said subject is a female who is pre-menopausal, perimenopausal, menopausal or post-menopausal.

4. The use of any one of Claims 1-3, wherein said subject exhibits one or more symptoms of pre-diabetes comprising: fasting blood glucose level of between 100 mg/dL and 125 mg/dl; blood sugar level of between 140 mg/dL and 199 mg/dL two hours after ingesting a 75 gram glucose solution or a glucose solution of 1.75 grams of glucose per kilogram of body weight, to a maximum dose of 75 grams; and/or glycated hemoglobin of between 5.7 percent and 6.4 percent.

5. The use of any one of Claims 1-3, wherein said subject exhibits one or more symptoms of diabetes comprising: fasting blood glucose level greater than 125 mg/dl; blood sugar level of at least 200 mg/dL two hours after ingesting a 75 gram glucose solution or a glucose solution of 1.75 grams of glucose per kilogram of body weight, to a maximum dose of 75 grams; and/or glycated hemoglobin of at least 6.5 percent.

6. The use of any one of Claims 1-3, wherein said subject exhibits one or more risk factors for development of type II diabetes comprising: family history of type II diabetes; one or more parents or siblings previously diagnosed with type II diabetes; dyslipidemia; total blood triglyceride levels of at least 200 mg/dL; blood high density lipoprotein level less than 35 mg/dL; obesity; body mass index

greater than 25 kg/m^2; history of gestational diabetes; previously gave birth to an infant with birth weight greater than 9 lbs.; hypertension; systolic blood pressure of at least 140 mmHg; diastolic blood pressure of at least 90 mmHg; previous measurement of fasting blood glucose of at least 99 mg/dL; vascular disease; Polycystic Ovarian Syndrome; or acanthosis nigricans.

7. The use of any one of Claims 1-3, wherein said subject has been diagnosed with type II diabetes.

8. The use of Claim 7, wherein said subject is refractory to treatment with GLP-1, exenatide-1, exendin, exendin analog, exendin agonist, liraglutide, exenatide LAR, a DPP-4 antagonist, a GLP-1 receptor agonist, or another GLP-1 agonist.

9. The use of any of Claims 1-8, wherein the medicament subsequent to administration does not significantly increase insulin secretion *in vivo* and/or result in an increased incidence in pancreatitis or the expression of markers or cytokines associated with pancreatic inflammation.

10. Use of an anti-CGRP antibody or antibody fragment comprising a VL polypeptide comprising CDR polypeptides comprising the sequences of SEQ ID NO: 55, 56 and 57 and a VH polypeptide comprising CDR polypeptides comprising the sequences of SEQ ID NO: 58, 59 and 60 in the manufacture of a medicament for treating dyslipidemia in a subject in need thereof.

11. The use of Claim 10, wherein the use is for increasing the ration of lean tissue to body fat in a subject in need thereof.

12. The use of Claim 10 or 11, wherein the subject is obese.

13. The use of Claim 12, wherein the subject is prediabetic or diabetic.

14. The use of any one of Claims 1-13, wherein said VL polypeptide comprises the amino acid sequence of SEQ ID NO: 51 and said VH polypeptide comprises the amino acid sequence of SEQ ID NO: 53.

15. The use of any one of Claims 1-13, wherein said antibody or antibody fragment comprises a light chain polypeptide having the sequence of SEQ ID NO: 52 and a heavy chain polypeptide having the sequence of SEQ ID NO: 54.

16. The use of any one of Claims 1-15, wherein an active agent other than said anti-CGRP antibody or antibody fragment of the medicament is also to be administered as part of the treatment.

17. The use of Claim 16, wherein said active agent comprises one or more of amylin, amylin agonist, sulfonylureas, calcitonin, glucagon, PPAR-gamma agonists, GPL-1 receptor agonists, dipeptidyl peptidase IV inhibitor, amylin analogs, biguanides, dopamine D2 receptor agonists, meglitinides, alpha-glucosidase inhibitor, antidyslipidemic bile acid sequestrant, exendin, exendin analog, exendin agonist, gastrin inhibitory peptide (GIP), incretin peptide, insulin, SGLT2 inhibitor, a glucose reabsorption inhibitor, fenofibrate, fibrate, an anti-ghrelin antibody or antibody fragment, an fibroblast growth factor receptor (FGFR)-l(IIIb), FGFR-l(IIIc), antibody or antibody fragment, and/or FGFR-4(IIIc), an anti-CD38 antibody or antibody fragment, an anti-MIC-1 antibody, or MIC-1 binding fragment, metformin or a combination of any of the foregoing.

18. The use of Claim 17, wherein said active agent is metformin.

19. The use of any one of Claims 1-18, wherein the dosage of the medicament is between about 0.1 and 100.0 mg/kg of body weight of recipient subject.

20. The use of any one of Claims 1-19, wherein said anti-CGRP antibody or antibody fragment is a humanized antibody or humanized antibody fragment.